Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
nHukuKpGMpXtdJNd
